REMARKABLE
17.3.2020 14:02:06 CET | Business Wire | Press release
reMarkable today announced its next-generation paper tablet, reMarkable 2. The breakthrough device for note-taking and reviewing documents without distractions comes from the Norwegian developers behind the original paper tablet, which broke pre-order records during its 2017 launch.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200317005154/en/
reMarkable 2 is available for pre-order from reMarkable.com for €399, and is set to ship in June 2020. The limited-time launch offer will include a Marker and Folio.
At 0.19 in/4.7 mm thick, reMarkable 2 is the world’s thinnest tablet. Armed with weeks of battery life, and the breakthrough second-generation CANVAS display partially powered by E Ink technology, reMarkable 2 is the most paper-like digital device the industry has ever seen.
“reMarkable 2 supports our design philosophy of helping people think better through powerful technology,” said Magnus Wanberg, CEO of reMarkable. “Our latest tablet is paper-thin and our innovations in display technology make it so much like writing on paper that it’s hard to tell the difference.”
Inspired by paper, reMarkable 2 is a tool for note-taking, reading, and annotating documents without built-in distractions. “Today’s world is a frenzied place of ever-evolving technology that increasingly demands more of our time and attention. reMarkable 2 is a step in a more human-friendly direction. It’s designed to help people think,” said Wanberg.
The company has spent the last six years developing and perfecting its breakthrough paper tablet to deliver a realistic paper experience that supports improved focus and better thinking, while still maintaining a connection to the digital world.
reMarkable 2 features the ability to convert handwritten notes into text, along with options for organizing, sharing, annotating and searching documents. Among a host of other digital features, reMarkable’s cloud service makes content accessible through multi-platform companion apps for desktop and mobile. Its feature set is aimed at anyone who likes writing by hand, but wants to be able to reuse their work in their digital workflow.
At launch, reMarkable 2 will be accompanied by a Google Chrome plug-in that will allow users to read clean, reformatted web articles on their paper tablet without distractions.
Innovations in ultra-thin, high-friction surface materials and a completely redesigned, second-generation CANVAS display, make reMarkable 2 an unprecedented digital paper device. Millions of physical ink particles lift to the display’s surface, working in tandem with the high precision Marker to deliver exceptional paper-like accuracy.
A range of accessories to compliment reMarkable 2
All accessories are either included in their respective launch bundles, available as a bundle upgrade, or can be purchased separately later in the year when the pre-order finishes.
Markers:
reMarkable 2 will launch with two different Markers, both of which attach magnetically to the right side of the paper tablet:
Marker - €59 (included in pre-order)
Marker Plus (includes built-in eraser in the top end) - €99
Folios
: Folio and Book Folio have been created with function and style in mind. They’re both made from fine materials and designed to fit reMarkable 2 perfectly.
Folio - €79 - The original sleeve for reMarkable 2 (included in the first part of pre-order)
Book Folio - from €99 - Lets you keep your reMarkable 2 in its cover while working. Attaches magnetically to reMarkable 2
About reMarkable
Based in Oslo, Norway, reMarkable is the leading innovator within the paper tablet category, developing breakthrough digital paper tablets for note-taking, reading, and reviewing documents. Its vision is to create human-friendly products to help people think better. For more information about reMarkable and its digital paper tablet, visit https://remarkable.com
YouTube: https://youtu.be/0dgXuStEm4U
Instagram: https://www.instagram.com/remarkable/
Facebook: https://www.facebook.com/remarkableAS
Twitter: https://twitter.com/remarkablepaper
#remarkablepaper
View source version on businesswire.com: https://www.businesswire.com/news/home/20200317005154/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom